CMTM7

Across TCGA pan-cancer cohorts, CMTM7 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CMTM7 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CMTM7 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CMTM7 expression acts as an unfavorable survival marker.

PDAC, LSCC, and HNSC are the cancer types where CMTM7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.617	0.814	.030	8	view →
LSCC	DFS	Median	II,III,IV	0.789	1.000	.005	3	view →
HNSC	OS	Median	IV	0.598	0.944	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CMTM7–PDAC (OS)

Open the PDAC breakdown →